The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
The Board of Directors of Intervacc resolves on a rights issue of approximately SEK 225 million
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER...Strangvac is back in stock on all launched markets
Stockholm, December 6, 2024 – Intervacc AB (publ) announces that Strangvac®, a vaccine against equine strangles, is now back in stock for delivery in all European markets where the vaccine has been launched. The company applied for Special Batch Release (SBR), to...Interim report January – September 2024
The Group in summary 01/07/24 01/07/23 01/01/24 01/01/23 Full year -30/09/24 -30/09/23 -30/09/24 -30/09/23 2023 Net sales 2 531 3 024 7 660 6 389 8 015 Operating result...Invitation to conference call and audiocast in connection with the interim report
Stockholm, November 11, 2024 – Intervacc AB (publ) will publish its interim report for the period January to September 2024 on Thursday 14 November 2024, at 08:30 CET. CEO Jonas Sohlman and CFO Jan Persson will present the report at a conference call and audiocast...Nyhetstjänster
